Bioengineering Innovative Solutions for Cancer bridges the gap between bioengineering and cancer biology. It focuses on a 'bottom up' understanding of the links between molecules, cells, tissues, organs, organisms, and health and functions-all within a bioengineering context. Chapters cover the main methods, technologies and devices that could help diagnose cancer sooner (e.g., ultrasensitive imaging and sensing technologies) and helpful treatments (e.g., new, more targeted therapies). The book takes an interdisciplinary approach that is ideal for those who need the latest information on design techniques and devices that help treat cancer using new, more targeted therapies.
By covering the many different ways engineers can deliver innovative solutions to tackle cancer, this book is a valuable read for researchers who have an ambition to make an impact on people's life in either an academic or industrial setting.
- Connects bioengineering and cancer biology, providing information on sensors, imaging, therapies and in-vitro models
- Presents the most comprehensive coverage in the field of cancer engineering to date
- Provides an academic introduction to (molecular) bioengineering for students, regardless of scientific background (math's, physics, chemistry, biology)
- Highlights the unmet medical needs for bioengineers and the main technological breakthroughs to cancer biologists
Please Note: This is an On Demand product, delivery may take up to 11 working days after payment has been received.
In 2010, Dr Sylvain Ladame was appointed lecturer in biosensor development at Imperial College London. Since then, he has been a key member of the "Cancer and Engineering initiative led by the departments of Bioengineering and Medicine at Imperial College and has been working on the engineering and validation of new chemical probes and devices for ultrasensitive sensing of circulating nucleic acids in blood as a mean to diagnose cancers early and non-invasively. His most recent work was published in Analytical Chemistry (2016) and was selected as ACS editors' choice. Sylvain is also the academic lead of a new 4-year molecular bioengineering degree that will be launched in the department of Bioengineering of imperial college in Oct. 2017.
Dr. Jason Y.H. Chang is currently a Postdoctoral research associate in Prof.Darrell Irvine's lab at the Koch Institute at MIT, working on nanotechnologies for HIV vaccine development and detection of cell-free miRNA in cancer models. Prior to MIT, he obtained his MEng (Hons) in Product Design Engineering at Loughborough University in 2009, and then joined Imperial College London to obtain his MSc in Bioengineering in 2010, followed by an internship at University of Arizona working on developing a medium-throughput VE-cadherin screening assay. In 2011, he returned to Imperial College to pursue his PhD in ocular biomechanics and drug delivery with Prof. Darryl Overby, where he worked on the development of a peptide-based biosensor to detect nitric oxide production in the eye and drug delivery platforms to decrease elevated intraocular pressure the primary risk factor for glaucoma. During this time he was also a visiting researcher at Duke University (2013-2014) working with Prof. W Daniel Stamer on pharmacological interventions to alleviate ocular hypertension in both animal and human eyes. After completing his PhD in 2016, he joined the Ladame group to help develop different platform technologies for prostate cancer diagnosis based on sensing of circulating miRNA biomarkers from liquid biopsies using engineered oligonucleotide-templated reactions.